The Significance of Results for Entrectinib in ROS1+ NSCLC

October 24, 2017
Robert C. Doebele, MD, PhD

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non–small cell lung cancer (NSCLC).